Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498803 | 0.98 | TDP1 (0.42) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL962814 | 0.94 | TDP1 (0.41) | CA1CA2CA12CA9TDP1 | |
| Hydrochloric Acid SCHEMBL17803469 | 0.93 | TDP1 (0.40) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL12142875 | 0.86 | TDP1 (0.39) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL3486538 | 0.85 | CA1 (0.40) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL1859283 | 0.85 | EPHX1 (0.43) | CA1CA2CA12CA9TDP1 | |
| Hydrochloric Acid SCHEMBL20450582 | 0.85 | TDP1 (0.38) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL5493650 | 0.84 | TDP1 (0.59) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL11496116 | 0.84 | CA1 (0.39) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL15341460 | 0.84 | EPHX1 (0.46) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20160120997-A1 | Modified Glycoproteins Having Circulating Half-Lives | NOVO NORDISK HEALTHCARE AG (CH) | 2016-05-05 | — | — | US | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2059527-B1 | MODIFIED GLYCOPROTEINS | NOVO NORDISK HEALTHCARE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| CN-101535339-B | Modified proteins | NOVO NORDISK HEALTHCARE AG | 2014-11-12 | — | — | CN | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-1688150-A1 | Process for the preparation of alkoxyamine functionalised poly ethylene glycols | NOVO NORDISK A/S (DK) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006079641-A2 | INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2006-08-03 | — | — | WO | disclosed |
| EP-1653996-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | Novo Nordisk Health Care AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654004-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006042847-A2 | METHOD FOR THE PREPARATION OF OXIME, THIAZOLIDINE, DITHIANE, DITHIOLANE OR HYDRAZONE LINKED ANALOGUES OF GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006042848-A2 | GROWTH HORMONE CONJUGATES | NOVO NORDISK A/S (DK) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006035057-A1 | MODIFIED PROTEINS | NOVO NORDISK HEALTH CARE AG (DK) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005014035-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTH CARE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014049-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | CA1 3988/4885CA2 4642/4885CA12 3043/4885 |
| US-20160120997-A1 | Modified Glycoproteins Having Circulating Half-Lives | SIGLEC7, FUT4, SELPLG | CA1 1787/4885CA2 3818/4885CA12 303/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | CA1 1661/4885CA2 2378/4885CA12 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.